Omnia TeleHealth

Omnia TeleHealth — Cash-pay direct-to-consumer GLP-1 longitudinal treatment records: repeat refill-visit encounters for established patients on semaglutide or tirzepatide, each capturing self-reported weight-loss progress, medication tolerance, side-effect review, dose and plan adjustments, prescription renewal or discontinuation decisions, and partner-pharmacy compounded-versus-brand dispensing routing. Micro-scale: an independent single-clinician telehealth practice, cash-pay at $69 per refill visit, no insurance billing, no disclosed funding, and absent from major business-data providers. …

Omnia TeleHealth offers (Alternative) — Small and finite: estimate low thousands to tens of thousands of total encounter notes across the practice's life (single founding provider, cash-pay at $69 per visit), each carrying a weight, tolerance, side-effect and decision entry. The genuinely interesting slice is narrow but hard to obtain elsewhere — a documented compounded-GLP-1 treatment cohort with renewal and discontinuation reasons recorded in free text.

Real-world GLP-1 tolerability and persistence outside insured and trial populations, compounded-versus-brand semaglutide and tirzepatide outcome comparison, cash-pay price-sensitivity and discontinuation analysis, direct-to-consumer weight-management dosing-pattern study, small-cohort qualitative safety signal review for side-effect escalation patterns

The data is with 3 years of history.

Coverage spans US; Health Care Services, Pharmaceuticals; alternative; equities.